中寵股份(002891.SZ)一季度淨利潤預增122.26%-172.58%
格隆匯 4 月 14日丨中寵股份(002891.SZ)公佈,預計2021年度第一季度歸屬於上市公司股東的淨利潤1838.33萬元-2254.60萬元,同比增長122.26%-172.58%。主要原因如下:
1、公司積極開拓國內市場,集中資源不斷夯實公司品牌及渠道能力,取得了良好的成效,公司國內銷售的規模穩定提升。
2、寵物食品作為寵物日常生活的必需品,海外市場在疫情期間仍然保持了良好的消費需求。得益於公司嚴格落實疫情防控措施,公司境外業務的訂單交付情況良好,公司的境外銷售收入實現穩定增長。
3、公司進一步加強成本費用管控,增強內部管理,推行精細化管理、提質降本增效,在一定程度上對業績產生了正向提升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.